This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

# Summary of Investigation Results Osimertinib mesilate

September 24, 2019

## Non-proprietary name

Osimertinib mesilate

## Branded name (Marketing authorization holder)

Tagrisso Tablets 40 mg, 80 mg (AstraZeneca K.K.)

#### **Indications**

EGFR gene mutation-positive inoperable or recurrent non-small cell lung cancer

# **Summary of revisions**

"Toxic epidermal necrolysis (TEN), oculomucocutaneous syndrome (Stevens-Johnson syndrome), erythema multiforme" should be added to the Clinically Significant Adverse Reactions section.

#### Investigation results and background of the revision

Cases of TEN, oculomucocutaneous syndrome, or erythema multiforme have been reported in patients treated with osimertinib mesilate in Japan and overseas. MHLW/PMDA concluded that revision of the package insert was necessary based on the results of their investigation of the currently available evidence and in consultation with expert advisors.

# Number of cases and patient mortalities reported in Japan during the previous 3 fiscal years

Toxic epidermal necrolysis
 No cases involving TEN have been reported to date.

**Pharmaceuticals and Medical Devices Agency** 

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <a href="mailto:safety.info@pmda.go.jp">safety.info@pmda.go.jp</a>



This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

#### 2. Oculomucocutaneous syndrome

A total of 5 cases involving oculomucocutaneous syndrome have been reported to date (including 2 cases for which a causal relationship between the drug and event could not be ruled out).

No patient mortalities have been reported to date.

3. Cases involving erythema multiforme\*

A total of 3 cases involving erythema multiforme have been reported to date (including 3 cases for which a causal relationship between the drug and event could not be ruled out).

No patient mortalities have been reported to date.

\*Cases considered erythema multiforme major according to the Guidelines for the Diagnosis and Treatment of Erythema Multiforme Exudativum Major, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (TEN) in Japan